Reporting Manager
Longitude Capital Partners V, LLC
Symbol
CTMX
Shares outstanding
158,061,110 shares
Disclosed Ownership
11,538,461 shares
Ownership
7.3%
Form type
SCHEDULE 13G
Filing time
20 May 2025, 21:00:40 UTC
Date of event
13 May 2025

Sponsored

Quoteable Key Fact

"Longitude Capital Partners V, LLC disclosed 7.3% ownership in CytomX Therapeutics, Inc. Common Stock, $0.00001 par value per share (CTMX) on 13 May 2025."

Quick Takeaways

  • Longitude Capital Partners V, LLC filed SCHEDULE 13G for CytomX Therapeutics, Inc. Common Stock, $0.00001 par value per share (CTMX).
  • Disclosed ownership: 7.3%.
  • Date of event: 13 May 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 20 May 2025, 21:00.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (4)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Longitude Capital Partners V, LLC 7.3% 11,538,461 0 11,538,461 /s/ Cristiana Blauth Oliveira Cristiana Blauth Oliveira, Authorized Signatory
Longitude Venture Partners V, L.P. 7.3% 11,538,461 0 11,538,461 /s/ Cristiana Blauth Oliveira Cristiana Blauth Oliveira, Authorized Signatory
Patrick G. Enright 7.3% 11,538,461 0 11,538,461 /s/ Cristiana Blauth Oliveira Cristiana Blauth Oliveira, as attorney-in-fact for Patrick G. Enright
Juliet Tammenoms Bakker 7.3% 11,538,461 0 11,538,461 /s/ Cristiana Blauth Oliveira Cristiana Blauth Oliveira, as attorney-in-fact for Juliet Tammenoms Bakker